Publication: Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
No Thumbnail Available
Identifiers
Date
2018
Authors
Argüelles Arias, Federico
Hinojosa Del Val, Joaquín
Vera Mendoza, Isabel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.
Description
MeSH Terms
Anti-Inflammatory Agents
Biosimilar Pharmaceuticals
Humans
Inflammatory Bowel Diseases
Infliximab
Practice Guidelines as Topic
Biosimilar Pharmaceuticals
Humans
Inflammatory Bowel Diseases
Infliximab
Practice Guidelines as Topic